Market Overview

UPDATE: Jefferies Downgrades Express Scripts to Hold; Maturing Earlier

Share:
Related ESRX
Earnings Scheduled For July 28, 2015
The 10 Worst Companies To Work For
Regeneron Aims For $1000 As Its Growth Accelerates Yet Again (Seeking Alpha)

Jefferies reduced its rating on Express Scripts (NASDAQ: ESRX) from Buy to Hold and lowered its price target from $70 to $56.

Jefferies said, "We are downgrading ESRX to Hold from Buy after mgmt commented last night that 2013 Street EPS expectations (currently at 21% Y/Y growth) are overly aggressive. While we had anticipated ESRX's growth rate to decelerate after synergies from its Medco acquisition are realized, it appears that ESRX is reaching its maturity point quicker than most investors had expected."

Express Scripts closed at $27.46 on Monday.

Latest Ratings for ESRX

DateFirmActionFromTo
Jun 2015OppenheimerInitiates Coverage onPerform
Jun 2015Deutsche BankMaintainsHold
Jun 2015Raymond JamesDowngradesOutperformMarket Perform

View More Analyst Ratings for ESRX
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (ESRX)

Get Benzinga's Newsletters